DIAMYD MEDICAL
Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical’s shares are traded on Nasdaq Stockholm First North, ticker DMYD B.
DIAMYD MEDICAL
Industry:
Biotechnology
Founded:
1994-01-01
Address:
Stockholm, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.diamyd.com
Total Employee:
1+
Status:
Active
Contact:
+46 8 661 00 26
Email Addresses:
[email protected]
Total Funding:
100 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Font Awesome Domain Not Resolving Global Site Tag Japanese Yen
Investors List
Pittsburgh Life Sciences Greenhouse
Pittsburgh Life Sciences Greenhouse investment in Pre Seed Round - Diamyd Medical
Official Site Inspections
http://www.diamyd.com Semrush global rank: 6.9 M Semrush visits lastest month: 706
- Host name: shww-0114.s.beebyte.se
- IP address: 185.133.206.132
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "Diamyd Medical"
Diamyd - Developing precision therapies for type 1 diabetes
With full speed ahead, we continue advancing Diamyd ® — our precision immunotherapy for Type 1 Diabetes — toward an FDA supported Phase-3 Study early read-out, that may be …See details»
Diamyd Medical - Wikipedia
Diamyd Medical AB (Stockholm NASDAQ, First North) is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for diabetes. The company is developing two products. The company is headquartered in Stockholm, and maintains a manufacturing facility in Umeå. See details»
Diamyd Medical - Crunchbase Company Profile
Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. GABA …See details»
Diamyd Medical - Developing precision therapies for type 1 diabetes
The Story of Diamyd Medical The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop type 1 diabetes in its tracks. The film also …See details»
Diamyd Medical and INNODIA partner for Type 1 Diabetes …
Nov 5, 2024 Diamyd Medical has entered a strategic partnership with INNODIA, an international non-profit organization dedicated to advancing research on disease modifying therapies for …See details»
Diamyd Medical - Overview, News & Similar companies - ZoomInfo
View Diamyd Medical (www.diamyd.com) location in Stockholm, Sweden , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
A Behind-the-Scenes Look at DIAGNODE-3
Feb 11, 2025 DIAGNODE-3 is a phase 3 clinical trial of the disease-modifying therapy Diamyd® that aims to preserve insulin-producing beta cells.See details»
Diamyd Medical AB - Cision News
Diamyd Medical will receive USD 1.75 million in expanded collaboration support from Breakthrough T1D (formerly JDRF), the world’s leading Type 1 Diabetes research and …See details»
Diamyd Medical – Wikipedia
Diamyd Medical är ett svenskt diabetesbolag verksamt inom läkemedelsutveckling. Diamyd Medicals aktie handlas på Nasdaq Stockholm First North under kortnamnet DMYD B.See details»
Available positions - diamyd.com
Since the organization is in a development phase, there are great opportunities to contribute during a very exciting and expansive period. The office is based in Stockholm City and you will …See details»
Diamyd Medical Aligns with FDA on Key Elements for an …
Dec 13, 2024 Diamyd Medical today announced a positive in-person Type C meeting with the U.S. Food and Drug Administration (FDA), where alignment was achieved on key components …See details»
In-depth analysis showing robust Diamyd® treatment effects …
Nov 6, 2024 These results demonstrate the effectiveness of Diamyd ® compared to placebo on preservation of C-peptide across individual trials and support the robustness of the currently …See details»
Diamyd Medical plans for GMP Certification in 2025
6 days ago The Umeå facility was acquired in 2021 and is owned through Diamyd Medical's wholly owned subsidiary Diamyd Biomanufacturing AB. Extensive renovations and upgrades …See details»
Årsredovisning 21/22 - diamyd.com
Beställning skickas till [email protected], eller per post till Diamyd Medical AB, Box 7349, 103 90 Stockholm. För ytterligare information, vänligen kontaktaUlf Hannelius, vd, tel +46 736 35 42 …See details»
Could AI Help Predict Type 1 Diabetes? Diamyd Medical Thinks So
2 days ago Diamyd Medical’s AI-powered screening improves early type 1 diabetes detection, helping at-risk individuals get personalized care sooner.See details»
Diamyd Medical meddelar ytterligare teckningsåtaganden för …
Om Diamyd Medical Diamyd Medical utvecklar precisionsmedicinska behandlingar för att förebygga och behandla typ 1-diabetes och LADA (Latent Autoimmune Diabetes in Adults). …See details»
Nordiclifescience.org: Recruitment drive underway at Diamyd …
Articles, interviews and events related to Diamyd Medicals research and activities.See details»
Diamyd Medical presenterar precisionsmedicinskt …
Oct 14, 2024 Diamyd Medical kommer under de närmaste veckorna att delta i två större konferenser: 50th Annual Meeting of the International Society for Pediatric and Adolescent …See details»
Nordiclifescience.org: Recruitment drive underway at Diamyd …
With the setup of a completely new facility within a highly technical and regulated industry, Johansson and her colleagues are paving the way for the development for future precision …See details»